107 related articles for article (PubMed ID: 30953466)
1. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
Beukhof CM; Brabander T; van Nederveen FH; van Velthuysen MF; de Rijke YB; Hofland LJ; Franssen GJH; Fröberg LAC; Kam BLR; Visser WE; de Herder WW; Peeters RP
BMC Cancer; 2019 Apr; 19(1):325. PubMed ID: 30953466
[TBL] [Abstract][Full Text] [Related]
2. Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues.
Raia S; Chiloiro S; Giampietro A; Maratta MG; Attili F; Brizi MG; Rufini V; De Marinis L; Pontecorvi A; Rindi G; Schinzari G; Bianchi A
Endocr Metab Immune Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38284724
[TBL] [Abstract][Full Text] [Related]
3. AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment.
Jaskula-Sztul R; Chen G; Dammalapati A; Harrison A; Tang W; Gong S; Chen H
J Mater Chem B; 2017 Jan; 5(1):151-159. PubMed ID: 28025618
[TBL] [Abstract][Full Text] [Related]
4. Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report.
Dell'Unto E; Rinzivillo M; Esposito G; Iannicelli E; Prosperi D; Panzuto F; Annibale B
Gastroenterol Rep (Oxf); 2024; 12():goae023. PubMed ID: 38634006
[No Abstract] [Full Text] [Related]
5. Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.
Grossrubatscher E; Fanciulli G; Pes L; Sesti F; Dolci C; de Cicco F; Colao A; Faggiano A; Nike Group
J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33138305
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis.
Lee DY; Kim YI
Clin Nucl Med; 2020 Aug; 45(8):604-610. PubMed ID: 32520503
[TBL] [Abstract][Full Text] [Related]
8. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
[TBL] [Abstract][Full Text] [Related]
9. A primer on the genetics of medullary thyroid cancer.
Larouche V; Akirov A; Thomas CM; Krzyzanowska MK; Ezzat S
Curr Oncol; 2019 Dec; 26(6):389-394. PubMed ID: 31896937
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
[TBL] [Abstract][Full Text] [Related]
11. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
[TBL] [Abstract][Full Text] [Related]
12. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Zhou L; Lu Y; Liu W; Wang S; Wang L; Zheng P; Zi G; Liu H; Liu W; Wei S
Exp Hematol Oncol; 2024 Mar; 13(1):26. PubMed ID: 38429828
[TBL] [Abstract][Full Text] [Related]
13. Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.
Al-Toubah T; Strosberg J; Hallanger-Johnson J; El-Haddad G
Front Endocrinol (Lausanne); 2023; 14():1187870. PubMed ID: 38053729
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of [
Hertelendi M; Belguenani O; Cherfi A; Folitar I; Kollar G; Polack BD
Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189646
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy.
Hofland J; Brabander T; Verburg FA; Feelders RA; de Herder WW
J Clin Endocrinol Metab; 2022 Nov; 107(12):3199-3208. PubMed ID: 36198028
[TBL] [Abstract][Full Text] [Related]
16. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
Satapathy S; Bal C
Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors.
Gubbi S; Vijayvergia N; Yu JQ; Klubo-Gwiezdzinska J; Koch CA
Horm Metab Res; 2022 Dec; 54(12):795-812. PubMed ID: 35878617
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.
Czajkowski M; Kaemmerer D; Sänger J; Sauter G; Wirtz RM; Schulz S; Lupp A
BMC Cancer; 2022 Jul; 22(1):740. PubMed ID: 35799158
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy in Thyroid Cancer.
Gubbi S; Koch CA; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2022; 13():896287. PubMed ID: 35712243
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
